How to Help Your Patients Save Money on Palforzia: A Provider's Guide to Savings Programs

Palforzia's $890/month list price has been one of the most significant barriers to patient access since its 2020 FDA approval. For families whose children need this treatment, cost has been a critical factor — and now with the July 2026 discontinuation adding urgency, helping patients navigate remaining savings options has become both a clinical and financial priority. This guide provides allergists and prescribers with practical tools to support patient affordability during the wind-down.

Understanding Palforzia's Cost Structure

Palforzia cost varies by treatment phase and dose configuration. Providers should help patients understand these differences when counseling on affordability:

Initial Dose Escalation pack: Approximately $54-$55 — the single-use card for the initial clinic day. Note: These packs are no longer available for new patients as of early 2026.

Up-Dosing packs (including 3 mg and other levels): Approximately $683-$770 per 30-45 day supply

Maintenance sachets (300 mg): Approximately $683-$1,405/month depending on pharmacy

The annualized cost for a patient in active Up-Dosing or Maintenance can exceed $10,000 at list price — before insurance negotiation or assistance programs are applied.

Tool 1: Manufacturer Copay Assistance — The Palforzia Copay Program

Stallergenes Greer operated the PALFORZIA Copay Assistance Program for commercially insured patients. At its height, this program substantially reduced out-of-pocket costs for eligible patients. As of the January 2026 discontinuation announcement, the program's wind-down timeline follows the product withdrawal.

Action for providers:

Contact the Palforzia Pathway Hub (1-844-PALFORZ / 1-844-725-3679) to determine current copay program eligibility and availability during the wind-down period

Have a staff member designated to check program status for each Palforzia patient at each refill cycle

Verify that your patients' commercial insurance meets eligibility requirements (Medicare/Medicaid patients are typically excluded from manufacturer copay programs)

Tool 2: Prior Authorization — Getting Insurance to Cover Palforzia

Every major commercial insurer requires prior authorization (PA) for Palforzia. As REMS-certified prescribers, allergists are positioned to navigate this process effectively. Standard PA criteria across insurers (Cigna, UHC, Aetna, BCBS, and others) typically require:

Documented confirmation of IgE-mediated peanut allergy (positive skin prick test ≥8mm or peanut-specific IgE ≥14 kUA/L)

Patient age within approved range (1-17 years for initiation)

Prescriber enrolled in the Palforzia REMS program (include your REMS enrollment number in PA documentation)

Documentation of injectable epinephrine access and patient education

Absence of contraindications (uncontrolled asthma, history of EoE)

For continuing treatment, some insurers (including UnitedHealthcare) authorize for 12-month periods with annual renewals requiring clinical response documentation. For patients mid-treatment during the wind-down, documenting ongoing clinical response (tolerance at current dose level, adherence, clinical benefit) strengthens renewal authorization requests.

Handling PA Denials: The Appeals Process

PA denials for Palforzia should always be appealed when the clinical indication is sound. Key strategies:

Request peer-to-peer review — speak directly with the insurance medical reviewer to present the case

Cite published clinical evidence (PALISADE trial data: 67% of treated patients tolerated ≥600 mg peanut protein without dose-limiting symptoms)

Document medical necessity with specific patient risk factors (history of anaphylaxis, severity of prior reactions, high peanut sIgE levels)

For patients already on Palforzia, emphasize that abrupt discontinuation reverses desensitization — insurance denying continuation coverage creates a medical safety issue

39,049+ patients found their medications in stock

39K+

Find Ovide In Stock Today →

Tool 3: Drug Discount Cards for Uninsured or Denied Patients

For patients who are uninsured or whose insurance doesn't cover Palforzia, GoodRx and SingleCare prescription discount cards can provide meaningful savings at participating specialty pharmacies. Current GoodRx pricing shows approximately $654 for common Palforzia up-dosing configurations — roughly 15% below the average retail price. These cards work only at cash-pay prices and cannot be combined with insurance.

Consider giving cash-paying patients a GoodRx code via the GoodRx for Providers program — providers can distribute GoodRx discount cards directly in their offices.

Tool 4: Patient Assistance Programs (PAPs) for Qualifying Patients

For low-income, uninsured, or underinsured patients, the Palforzia PAP (if still operational during wind-down) can provide the medication at significantly reduced or no cost. Have your financial counselor or prior authorization team contact the Palforzia Pathway Hub (1-844-PALFORZ) to verify PAP eligibility criteria and application process during the remaining wind-down period.

Skip the calls, skip the stress.

Find Ovide In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

Planning for the Most Cost-Effective Transition After July 2026

As Palforzia supply ends, transitioning patients to office-based peanut OIT is typically the most cost-effective alternative. The cost of peanut flour, measuring equipment, and supplies typically runs well under $300 total — a fraction of Palforzia's annual cost. Insurance coverage of office-based OIT is inconsistent (it is off-label), but the clinical approach is similar. For patients whose primary need is multi-allergen protection, omalizumab (Xolair) may be covered by insurance for its food allergy indication. Work with your billing team to verify coverage pathways before recommending.

How medfinder Supports Provider Patient Access

During the Palforzia wind-down, medfinder for providers helps your team efficiently identify which specialty pharmacies still carry your patients' specific Palforzia dose levels. Rather than having staff spend time on hold calling multiple pharmacies, medfinder searches on your behalf and delivers results. This is particularly valuable when managing multiple patients at different dosing stages — each needing a different Palforzia product configuration.

Provider Action Checklist: Palforzia Patient Savings Support

Call 1-844-PALFORZ to confirm current copay assistance program availability during wind-down

Submit PA documentation proactively before each authorization cycle ends — don't wait for gaps in coverage

Offer GoodRx codes to cash-paying patients as a bridge option

Verify PAP eligibility for uninsured/underinsured patients with income below program thresholds

Begin counseling all Palforzia patients on the cost implications of transition alternatives (office-based OIT vs. Xolair) before they are forced to transition under supply pressure

Use medfinder to locate pharmacy inventory efficiently for each patient's dose configuration